GALDERMA
Galderma, the emerging pure-play dermatology category leader, is proud to present “NEXT by Galderma.” A ground-breaking report, NEXT takes a deep-dive into the global aesthetics trends set to shape 2024 and beyond. This project is the culmination of a year of comprehensive trend-forecasting research, conducted in collaboration with a network of renowned experts.
Aesthetics is increasingly becoming part of holistic beauty and well-being routines, which are, in turn, driving the category’s projected growth. By 2028, the aesthetics market is predicted to nearly double in value, reaching $25.9 billion.1
NEXT by Galderma offers a future-forward perspective on the aesthetics industry. The report identifies six key emerging trends, bolstered by three core macro movements that are supporting industry growth. These six key trends have the potential to shape the aesthetics landscape and become mainstream in the future. The report takes an in-depth look at these trends from a neutral standpoint, as well as at the societal and cultural aspects underpinning the evolution of the aesthetics industry.
Commissioned by Galderma and based on research from a leading trend-forecasting authority, the report is informed by extensive data and analysis. NEXT by Galderma was co-developed by a network of almost 40 of the world’s leading healthcare professionals and esteemed beauty and skincare influencers.
“In partnership with a renowned trend-forecasting agency, and in collaboration with revered healthcare professionals and influencers, we’ve identified six trends poised to shape the future of aesthetics. The trends that we see emerging now have the potential to become bigger and impact consumer decisions regarding their beauty and skincare choices. At Galderma, everything we do in the world of aesthetics is a manifestation of our belief in “Aesthetic Possibilities, Shaped Together.” It’s a new, more collaborative and future-facing approach that is at the core of NEXT by Galderma.”
GERRY MUHLE HEAD OF GLOBAL PRODUCT STRATEGY GALDERMA
|
NEXT by Galderma: The six trends that are anticipated to shape consumer demand in aesthetics
- Proactive Beauty: Addressing aging before it is apparent has become paramount. The rise of “prejuvenation” treatments, which focus on prevention rather than cure, reflects today’s zeitgeist. For aesthetics, this means an increased shift toward early intervention.
- Mindful Aesthetics: The ethos of mindful beauty has reached the aesthetics market. Consumers are increasingly embracing products with minimal environmental impact that align with their ethical values and provide natural-looking results. Additionally, there is demand for products that seamlessly integrate with the body, indicating a push-back against artifice.
- Fast Aesthetics: That trends in fashion and cosmetics come and go is nothing new. But the addition of aesthetics treatments into the mix is a more recent—and noteworthy—development. More and more people now want to use aesthetics to mimic the latest fast-moving trends.
- Beauty Fandom: There is a new and more extreme take on fandom at play in the aesthetics world today. This trend indulges in fascination with niche idolization—from cultural icons to digital filters, anime, and beyond—which is leading to a desire for metamorphosis.
- Expressionality: There is greater interplay between a sense of self and self-expression. We live in an era that encourages individuality in fashion, styling, hair, makeup and, now, aesthetic treatments. This trend celebrates the empowerment that comes from creating and enhancing one’s identity with aesthetics.
- Cancelling Age: Beauty today is for every age, at any age. We are cancelling expectations of what certain ages “should look like,” as consumers employ aesthetics to express their ageless attitude. This trend shows how the evolving desire to not be defined by our age is increasing demand to preserve and enhance beauty, rather than solely reverse aging.
The six trends are underpinned by three macro movements:
- Increasing accessibility: More convenient, more affordable, more inclusive. The exponential rise of minimally invasive treatments, as well as increased access to treatments via new clinic locations and treatment options, are factors that have reshaped the beauty industry. The desire for inclusivity has had a major impact on the world of aesthetics at large.
- Advancements in science and technology: The rise of aesthetic tech, new product innovations and improvements on existing products have expanded not only the variety of treatment options available, but also their appeal.
- Social community: Social media has heightened consumer awareness and understanding around aesthetic treatments. Aesthetic practitioners are using social media to garner sizeable followings, highlighting that the world of aesthetics has a far-reaching platform of increasing influence.
As Galderma continues to navigate what lies ahead, driven by “Aesthetic Possibilities, Shaped Together,” there remains a firm focus on advancing dermatology for every skin story. The skin we’re in shapes our lives. That’s why Galderma’s unparalleled portfolio—along with our commitment to staying at the forefront of emerging technologies, medical education, thought leadership and training—is essential to shaping the future of aesthetics.
To view the abridged version of the NEXT by Galderma report, click here.
About Galderma
Galderma is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ—the skin—meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we’re in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
References:
- Markets and Markets (2022): Medical Aesthetics Market - Global Forecast to 2027. Hadapsar: Markets and Markets, pp. 1–257. Available at: https://www.marketsandmarkets.com/Market-Reports/medical-aesthetics-market-885.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240206624555/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press release
Ranks 125th Among 500 Companies Around the GlobeTop 10% in the Environmental Sector Among 3,000 Major Global Companies Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 10
Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa
ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release
Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom